| Q82449410 | Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity |
| Q41272827 | Calcium channel blockers and hypertension: 2. Safety issues |
| Q41690938 | Calcium channel blockers: association with myocardial infarction, mortality, and cancer |
| Q41670487 | Clinical pharmacokinetics of nifedipine. Implications for the care of the elderly |
| Q77107601 | Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension |
| Q40574259 | Do calcium channel blockers have renal protective effects? |
| Q35660816 | Evolving role of calcium antagonists in the management of hypertension |
| Q35170117 | Has the role of calcium channel blockers in treating hypertension finally been defined? |
| Q27025771 | Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS |
| Q58998629 | Meta-Analysis of the Hemodynamic Properties of Antihypertensive Medications |
| Q35201251 | Method development and validation study for quantitative determination of nifedipine and related substances by ultra-high-performance liquid chromatography |
| Q33755752 | Role of a third generation calcium antagonist in the management of hypertension |
| Q41500150 | The calcium antagonist controversy: the emerging importance of drug formulation as a determinant of risk |
| Q41143980 | The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties |